Drug intelligence / Profile preview

INO-9112

Development stage: Unknown
Lead developer: Inovio Pharmaceuticals
Modality: DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Prophylactic Vaccines → Vaccines & Immunotherapeutics
Administration: Intradermal, Intramuscular

Overview

INO-9112 is a DNA vaccine and immune activator developed by Inovio Pharmaceuticals. It encodes human interleukin 12 (IL-12) and is designed to enhance immune responses, particularly in the context of chronic hepatitis B infection. The drug acts as an interleukin-2 receptor alpha chain (IL2RA) agonist, stimulating immune pathways to boost antiviral activity. INO-9112 has been studied primarily as an adjunct to other immunotherapies, such as INO-1800, in clinical trials for chronic hepatitis B and was also investigated for potential use in COVID-19 vaccine regimens. Its development status is discontinued[1][2][3][4][5].

Targets

IL-12R (Interleukin-12 receptor)

Beyond the preview

Go deeper on INO-9112.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INO-9112.

Explore the full profile